Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
Background Surrogates of antiviral efficacy are needed for COVID-19. We aimed to
investigate the relationship between the virological effect of treatment and clinical efficacy as …
investigate the relationship between the virological effect of treatment and clinical efficacy as …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: systematic review and meta …
KM Souza, G Carrasco, R Rojas-Cortés… - Plos one, 2023 - journals.plos.org
Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
A Qaseem, V Snow, JT Cross Jr… - Annals of internal …, 2008 - acpjournals.org
Description: The American College of Physicians and American Academy of Family
Physicians developed this guideline to present the available evidence on current …
Physicians developed this guideline to present the available evidence on current …
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …
Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during …
LE Wee, AT Tay, C Chiew, BE Young, B Wong… - Clinical Microbiology …, 2023 - Elsevier
Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19
Objective To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …